Location History:
- Zürich, CH (2010 - 2016)
- Zurich, CH (2013 - 2022)
Company Filing History:
Years Active: 2010-2022
Title: Heiko Henze: Innovating in Peptidomimetics
Introduction
Heiko Henze, an accomplished inventor located in Zurich, Switzerland, has made significant contributions to the field of medicinal chemistry. With a remarkable portfolio of 15 patents, Henze's work focuses on developing innovative solutions with potential applications in cancer treatment.
Latest Patents
His latest inventions include a series of template-fixed peptidomimetics, specifically Cyclo(-Tyr-His-X-Cys-Ser-Ala-Pro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys-Pro-Pro). These compounds feature a disulfide bond between Cys4 and Cys11, and pharmaceutically acceptable salts thereof. Notably, with X being either Ala or Tyr, these peptidomimetics demonstrate CXCR4 antagonizing properties, offering promising avenues for treating cancers mediated by CXCR4 receptor activity.
Career Highlights
Throughout his career, Heiko Henze has worked with renowned organizations such as Polyphor Ltd. and Universität Zürich, where he has continued to advance his research and development in the field of peptides and medicinal applications. His innovative spirit and dedication to science have earned him respect among peers and the scientific community at large.
Collaborations
Henze has collaborated with notable professionals in his field, including Frank Gombert and Daniel Obrecht. Together, they have shared knowledge and expertise to drive advancements in their research projects, emphasizing the importance of teamwork in achieving scientific breakthroughs.
Conclusion
Heiko Henze's contributions to the field of peptidomimetics underscore his role as a leading inventor in medicinal chemistry. His innovative patents not only illustrate his ability to push the boundaries of science but also highlight his commitment to developing therapeutic solutions that may one day improve cancer treatment. As he continues to innovate, the impact of his work will resonate within both academic and commercial sectors.